ASH 2014: Novel agents, including daratumumab and carfilzomib, in myeloma

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Philippe Moreau (University Hospital of Nantes, France) discusses novel agents in the management of multiple myeloma.

An open-label, multicentre, phase Ib study of the human anti-CD38 monoclonal antibody, daratumumab, in combination with backbone regimens in multiple myeloma, including bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone, is ongoing.

The phase III ASPIRE study showed that addition of carfilzomib to lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed multiple myeloma resulted in a statistically significant improvement in progression-free survival.

Year of Production:
Running Time:
Color/Sound:

2015
2:57
Color/Sound

Comments are closed.